Virtu KCG Holdings’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Virtu KCG Holdings’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$249K	Buy	+7,883	New	+$194K	0.01%	1902

Other funds holding RETA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu KCG Holdings's RETA Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2017: 7,883 shares worth $249K. The stake represents 0.01% of the portfolio and ranks #1902 among its holdings.

57 funds tracked by Wall St. Rank hold RETA as of Q2 2017.

Virtu KCG Holdings held 7,883 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $249K as of Q2 2017.
Reata Pharmaceuticals, Inc. Class A Common Stock was a new Virtu KCG Holdings position in Q2 2017.
Reata Pharmaceuticals, Inc. Class A Common Stock made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1902 holding.
57 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.